AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation

The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of non –small cell lung cancer (NSCLC) patients, with higher objective response rates and increased progression-free survival compared to former cytotoxic chemotherapy [1–3]. However, durable responses cannot be achieved as acquired resistance to EGFR TKIs inevitably develops [4]. Therefore, investigat ion into the molecular mechanisms of acquired resistance and subsequent development of novel drugs to overcome such resistance are essential in the treatment of NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research